What is CinCor Pharma, Inc. (CINC)?

CinCor Pharma, Inc. (CINC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CINC?

The current price of CINC is $29.06. Prices are updated in real time on Stocks360.

What is CINC's price-to-earnings (PE) ratio?

CINC's trailing twelve-month PE ratio is -20.46, based on current price and earnings per share data available on Stocks360.

What is CINC's market capitalization?

CINC's market capitalization is $1,271,790,558.00, placing it in the small-cap tier.

CinCor Pharma, Inc. (CINC)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$29.06

Market Cap

$1.27B

PE (TTM)

-20.46

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.00

Day Range

$29.02 – $29.35

52-wk Range

$10.53 – $43.15

Avg Volume

N/A

Volume

0.00

CinCor Pharma, Inc. (CINC) is a publicly traded company in the Healthcare sector. Latest price: $29.06. Market cap $1.27B. Trailing PE -20.46. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Nov 3, 2022

EPS $-0.51 vs est. $-0.61

Beat by $0.10

Proprietary Signals

Signal snapshot temporarily unavailable.

About CinCor Pharma, Inc.

CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-20.46×
P/S (TTM)	0.00×
P/B	-16.15×
PEG	0.23×
P/FCF (TTM)	-41.23×
EV / EBITDA	-32.78×
EV / Sales	0.00×
Earnings Yield	-4.89%
Free Cash Flow Yield	-2.43%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.14B
Net Income (TTM)	-$62.21M
Free Cash Flow (TTM)	-$30.85M
Net Debt	-$136.61M
Working Capital	$124.56M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	110.68%
Return on Invested Capital	-34.11%